Ionis Pharmaceuticals Announces Positive Donidalorsen Results for Hereditary Angioedema Published in JACI In Practice

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) is one of the best mid cap pharma stocks to buy. On July 21, Ionis Pharmaceuticals announced that positive results from the Phase 3 OASISplus prospective switch study of donidalorsen in patients with hereditary angioedema/HA were published in The Journal of Allergy and Clinical Immunology/JACI In Practice.

Hereditary angioedema is a rare and potentially life-threatening genetic condition characterized by recurrent attacks of severe swelling in various parts of the body. Donidalorsen is an investigational RNA-targeted medicine designed to target prekallikrein/PKK, which plays a role in activating inflammatory mediators associated with acute HAE attacks.

Ionis Pharmaceuticals Announces Positive Donidalorsen Results for Hereditary Angioedema Published in JACI In Practice

A close up photograph of a vial of a new biotechnological drug candidate in development.

The OASISplus switch cohort evaluated the safety and efficacy of donidalorsen, administered every four weeks, in patients who had previously been treated with other prophylactic treatments for at least 12 weeks. Results showed that patients were able to switch to donidalorsen without an increase in breakthrough attacks. Donidalorsen demonstrated a favorable safety profile and was well-tolerated.

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) is a commercial-stage biotechnology company that provides RNA-targeted medicines in the US.

While we acknowledge the potential of IONS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IONS and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.